BLASUBCUTANEOUSSOLUTION
Approved
Jun 2017
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
5/8 — Partial
RITUXAN HYCELA (rituximab and hyaluronidase) by Roche is cd20-directed antibody interactions [moa]. Approved for cd20-directed cytolytic antibody [epc]. First approved in 2017.
Drug data last refreshed 18h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RITUXAN HYCELA is a subcutaneous formulation combining rituximab (a CD20-directed monoclonal antibody) with hyaluronidase, enabling at-home administration for patients with B-cell non-Hodgkin lymphomas and select other hematologic malignancies. The hyaluronidase component temporarily breaks down hyaluronic acid in subcutaneous tissue, allowing rapid subcutaneous delivery of the full rituximab dose. This combination targets CD20-positive B cells, triggering antibody-dependent cell-mediated cytotoxicity and direct apoptosis.
$0.638MPart D
PeakProduct is at peak maturity with modest Part D spending (93 claims in 2023), indicating a stable but limited commercial footprint requiring targeted payer and physician engagement strategies.
Mechanism of Action
CD20-directed Antibody Interactions
Pharmacologic Class:
CD20-directed Cytolytic Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
Started Apr 2021
3 enrolled
Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular Lymphoma+11 more
Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy
Started Jun 2019
15 enrolled
Cutaneous Melanoma, Stage IIICutaneous Melanoma, Stage IVStage III Melanoma+5 more
Worked on RITUXAN HYCELA at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.